読み込み中
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
終値時点
$1.62
−$0.01 · -0.61%
時間外
$1.69
+$0.07 · +4.32%
10月12日 16:57 ET
日中の時刻はETです。市場データは遅延する場合があります。
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
日中レンジ
現在 $1.62
52週レンジ
現在 $1.62
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
49
適正価値
センチメント
61
強気
リスク
60
やや高いリスク
モメンタム
43
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
日中レンジ
現在 $1.62
52週レンジ
現在 $1.62
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1527.82万 EUR | 1890.5万 EUR | 651.4万 EUR | 359.4万 EUR | 133.5万 EUR |
| 売上原価 | 259.63万 EUR | — | — | — | — |
| 粗利益 | 1268.19万 EUR | 1890.5万 EUR | 651.4万 EUR | 359.4万 EUR | 133.5万 EUR |
| 研究開発 | 4071.79万 EUR | 3635.6万 EUR | 2514.8万 EUR | 5086.7万 EUR | 4222万 EUR |
| 販売・一般管理 | 1506万 EUR | 1366.1万 EUR | 1623.6万 EUR | 1865.1万 EUR | 1736.8万 EUR |
| 営業費用 | 5483.68万 EUR | 4937.7万 EUR | 3837.3万 EUR | 6875.3万 EUR | 5854.5万 EUR |
| 受取利息 | 224.09万 EUR | 325.1万 EUR | 259.3万 EUR | 10.6万 EUR | 5000 EUR |
| 支払利息 | 86.64万 EUR | 107.7万 EUR | 120.3万 EUR | 512.7万 EUR | 340.5万 EUR |
| 減価償却費と償却費 | 270.3万 EUR | 276.1万 EUR | 251.3万 EUR | 252.1万 EUR | 232.9万 EUR |
| 営業利益 | −4215.49万 EUR | −3047.2万 EUR | −3185.9万 EUR | −6515.9万 EUR | −5721万 EUR |
| 純利益 | −4051.91万 EUR | −2776.3万 EUR | −2811.9万 EUR | −6442.4万 EUR | −6074万 EUR |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$3.00
上昇余地（85.19%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
